Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial
Clinical Obesity · 2023-08 · 13 (4)
DOI: 10.1111/cob.12589 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Obesity, online erschienen am 11.03.2023. Verfasst von Ronette L Kolotkin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Quality of Life Consulting, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Quality of Life, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Novo Nordisk A/S.
Abstract (Originalsprache)
We assessed the effect of semaglutide 2.4 and 1.7 mg versus placebo on weight‐related quality of life (WRQOL) and health‐related quality of life (HRQOL) in the STEP 6 trial. Adults from East Asia (body mass index [BMI] ≥27.0 kg/m 2 with ≥2 weight‐related comorbidities, or ≥35.0 kg/m 2 with ≥1 weight‐related comorbidity) were randomized 4:1:2:1 to once‐weekly subcutaneous semaglutide 2.4 mg or placebo, or semaglutide 1.7 mg or placebo, plus lifestyle intervention for 68 weeks. WRQOL and HRQOL were assessed from baseline to Week 68 using the Impact of Weight on Quality of Life‐Lite Clinical Trials Version (IWQOL‐Lite‐CT) and the 36‐Item‐Short‐Form‐Survey‐version‐2.0 acute (SF‐36v2), with changes in scores by categories of baseline BMI (
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Quality of Life Consulting, Durham, North Carolina, USA.
- Family Medicine and Community Health, Duke University School of Medicine, Durham, North Carolina, USA.
- Centre of Health Research, Helse Førde Hospital Trust, Førde, Norway.
- Morbid Obesity Centre, Vestfold Hospital Trust, Tønsberg, Norway.
- Novo Nordisk A/S, Søborg, Denmark.
- Family Medicine Clinic and Biomedical Research Institute, Pusan National University Yangsan Hospital, Yangsan-si, Gyeongsangnam-do, South Korea.
ORCID-Profile: Ronette L Kolotkin
Förderung
- Novo Nordisk A/S
Zitieren
APA
Kolotkin, R. L., Jeppesen, O. K., Baker-Knight, J., Lee, S. Y., Tokita, A., & Kadowaki, T. (2023). Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial. Clinical Obesity, 13(4). https://doi.org/10.1111/cob.12589
Vancouver
Kolotkin RL, Jeppesen OK, Baker-Knight J, Lee SY, Tokita A, Kadowaki T. Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial. Clinical Obesity. 2023;13(4). doi:10.1111/cob.12589
BibTeX
@article{Kolotkin2023,
author = {Kolotkin, Ronette L and Jeppesen, Ole Kleist and Baker-Knight, James and Lee, Sang Yeoup and Tokita, Asako and Kadowaki, Takashi},
title = {Effect of once‐weekly subcutaneous semaglutide 2.4 mg on weight‐ and health‐related quality of life in an East Asian population: Patient‐reported outcomes from the STEP 6 trial},
journal = {Clinical Obesity},
year = {2023},
volume = {13},
number = {4},
doi = {10.1111/cob.12589}
}
EUVIMED